Medincell stock breaks its support at €24.10 and slides toward a new low
Medincell declined sharply on Monday in an almost stable Paris market, deepening its downtrend observed over several weeks. The stock broke a technical support level during the session, intensifying selling pressure noted since the beginning of the month.
A support broken during the session that isolates the stock among the strongest declines in the index
The Medincell stock fell 3.86% to €23.92 during trading, while the CAC 40 and SBF 120 remained near equilibrium (around -0.01% each). This decline places the stock among the strongest declines of the SBF 120 at mid-session. The move is all the more notable as the stock broke its support at €24.10 during the session and failed to recover it, with the price fluctuating around €23.94.
This downward breach of a level tested several times reinforces the short-term bearish configuration. The situation of moving averages confirms this dynamic: the stock is trading below the 20-day MA (€24.95, difference of -4.13%), the 50-day MA (€25.97, difference of -7.89%) and the 200-day MA (€25.59, difference of -6.53%), three benchmarks aligned above the current price. The RSI at 47, close to the neutral zone, does not yet indicate marked selling exhaustion, which leaves the configuration open to a continuation of the decline.
A decline that reflects a degraded quarterly trend, despite identified commercial prospects
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Over one month, Medincell lost 7%, and nearly 12% over three months, erasing part of the annual gain which remains positive at +33.56% over twelve months. This short-term tension contrasts with the prospects identified when the 2025/2026 fiscal year results were published on June 16, 2026: the company anticipated the commercial launch of Olanzapine LAI in the fourth quarter of 2026 and expected continued growth in UZEDY royalties. These elements represent the main operational levers expected in the coming months.
On the risk side, the company had noted a foreseeable increase in its operating expenses linked to its development. From a valuation perspective, the consensus of surveyed analysts anticipates a gradual return to profitability: the stock is currently trading at approximately 57 times the expected earnings for the following fiscal year, still a high multiple that reflects the company's growth profile. The nearest resistance is identified at €26.88, approximately 12% above the current price.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2025
Guidance from the release
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
